AstraZeneca

FDA OK for Pivekimab Sunirine-pvzy (Decnupaz)

FDA · blastic plasmacytoid dendritic cell neoplasm · 5 min

The US FDA has approved AbbVie's antibody-drug conjugate, Decnupaz (pivekimab sunirine-pvzy), for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks AbbVie's first ADC entry in the blood cancer space and the first ADC approval for this ultra-rare indication.

Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients

FDA · breast cancer · 7 min

The FDA has granted Priority Review to Datroway for the treatment of metastatic triple-negative breast cancer (TNBC) in patients not eligible for immunotherapy. This designation marks a significant step for AstraZeneca and offers a potential new therapeutic avenue for a challenging cancer subtype.

FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

FDA · hypertension · 7 min

The FDA has approved AstraZeneca's baxdrostat (Baxfendy), the first-in-class aldosterone synthase inhibitor, for adults with uncontrolled hypertension. This landmark approval offers a new therapeutic option for patients with difficult-to-treat hypertension.

ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address

7 min

The ASCO 2026 annual meeting presented a subdued landscape for European pharmaceutical giants like AstraZeneca and Roche, highlighting areas where both companies need to intensify their strategic efforts. Despite a quiet conference, significant market dynamics are at play for these oncology leaders.